| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | AIO; AIOLOS; ZNFN1A3 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human IKZF3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IKZF3抗体的模拟参考文献示例(实际文献需通过学术数据库检索确认)：
1. **文献名称**：*IKZF3/Aiolos regulates B-cell development and function in autoimmune disorders*
**作者**：Smith J, et al.
**摘要**：研究通过免疫沉淀和Western blot分析，使用IKZF3抗体揭示了其在B细胞分化中的调控作用，表明IKZF3缺失导致自身免疫小鼠模型中异常B细胞活化。
2. **文献名称**：*Degradation of IKZF3 by immunomodulatory drugs enhances antitumor immunity in multiple myeloma*
**作者**：Wang L, et al.
**摘要**：利用IKZF3抗体检测来那度胺等药物对多发性骨髓瘤细胞的影响，发现药物通过促进IKZF3蛋白降解增强T细胞介导的抗肿瘤反应。
3. **文献名称**：*IKZF3 mutations drive chronic lymphocytic leukemia progression via impaired transcriptional repression*
**作者**：Garcia-Ruiz C, et al.
**摘要**：通过免疫组化(IHC)和流式细胞术分析IKZF3表达，发现CLL患者中IKZF3突变导致其转录抑制功能丧失，促进癌细胞增殖。
4. **文献名称**：*Aiolos (IKZF3) as a therapeutic target in systemic lupus erythematosus*
**作者**：Kim H, et al.
**摘要**：研究使用IKZF3抗体阻断实验，证实靶向IKZF3可减少狼疮模型小鼠的浆细胞过度活化，提示其作为SLE治疗的潜在靶点。
**注意**：以上为模拟示例，实际文献需结合具体研究需求在PubMed、Google Scholar等平台检索。
IKZF3 antibodies target the IKAROS family zinc finger protein 3 (IKZF3), also known as Aiolos, a transcription factor critical for immune regulation. Encoded by the IKZF3 gene, Aiolos contains zinc finger domains that mediate DNA binding and protein interactions, playing a key role in lymphocyte development, B-cell differentiation, and plasma cell function. It regulates gene expression by interacting with chromatin-remodeling complexes and other transcription factors.
IKZF3 antibodies are primarily used in research to study protein expression, localization, and interactions in immune cells. Dysregulation of IKZF3 is implicated in diseases like B-cell malignancies (e.g., multiple myeloma, chronic lymphocytic leukemia) and autoimmune disorders. For example, IKZF3 overexpression in cancer correlates with aggressive disease and drug resistance, making it a therapeutic target. Drugs like lenalidomide promote IKZF3 degradation, highlighting its clinical relevance. In autoimmunity, IKZF3 variants are linked to altered immune tolerance, as seen in systemic lupus erythematosus.
These antibodies enable detection of IKZF3 in techniques such as Western blot, immunohistochemistry, and flow cytometry, aiding mechanistic studies. Their development also supports diagnostic applications, such as assessing IKZF3 levels to predict treatment responses. Research on IKZF3 continues to uncover its dual roles in immune homeostasis and disease, driving interest in therapeutic strategies targeting its pathways.
×
